Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.33 |
| ▸ | TACR3 | P29371 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5347709 | 0.97 | POLB (0.40) | POLBHTTTACR1TSHRTACR3 | |
| SCHEMBL5346731 | 0.88 | TACR1 (0.43) | POLBHTTTACR1TSHRTACR3 | |
| SCHEMBL5353821 | 0.87 | POLB (0.40) | POLBHTTTACR1TSHRTACR3 | |
| SCHEMBL5347316 | 0.87 | HTT (0.43) | POLBHTTTACR1TSHRTACR3 | |
| SCHEMBL5344532 | 0.87 | POLB (0.40) | POLBHTTTACR1TSHRTACR3 | |
| SCHEMBL5341114 | 0.86 | EZH2 (0.43) | POLBHTTHPGD | |
| SCHEMBL5347456 | 0.86 | POLB (0.39) | POLBHTTTACR1TSHRTACR3 | |
| SCHEMBL5344713 | 0.85 | POLB (0.38) | POLBHTTTACR1TSHRTACR3 | |
| SCHEMBL28748093 | 0.85 | POLB (0.38) | POLBHTTTACR1TSHRTACR3 | |
| SCHEMBL5344995 | 0.85 | LMNA (0.44) | POLBHTTTSHRALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160966-B2 | 2,2,6,6 Diethyl-dimethyl-1-alkoxy-piperidine compounds and their corresponding 1-oxides | CIBA SPECIALTY CHEMICALS CORP. (US) | 2007-01-09 | — | — | US | disclosed |
| US-20050143539-A1 | 2,2,6,6 Diethyl-dimethyl-1-alkoxy-piperidine compounds and their corresponding 1-oxides | NESVADBA PETER (CH) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143539-A1 | 2,2,6,6 Diethyl-dimethyl-1-alkoxy-piperidine compounds and their corresponding 1-oxides | ALKBH2, NFE2L2, DPYSL2 | POLB 465/4885HTT 3742/4885TACR1 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.